FDA rejects Replimune’s oncolytic virus
There are questions about vuso-vec’s supporting and confirmatory trials.
Columvi avoids its worst-case scenario
Roche’s drug is knocked back in second-line lymphoma, but keeps its third-line nod.
Reblozyl flops in a new anaemia use
The Bristol/Merck’s drug’s hopes in myelofibrosis have taken a blow.
Adcom puts up a Blenrep roadblock
A surprising no to both multiple myeloma uses puts the ball in the FDA's court.
Boehringer slims down in SIRPα
The group has canned its first-generation project, hoping that a follow-on will reach more patients.
Bristol pulls ahead of Amgen
The company will start a phase 2/3 trial of its Mirati-originated PRMT5 inhibitor in autumn.
Sino takes out the rest of Merck’s partner
LaNova, which licensed a PD-1 x VEGF to Merck, is acquired by another Chinese player.
PMV hopes for rezatapopt redemption
The disappointing Pynnacle trial is set to yield registrational data.
Pivotal T-cell engager readouts approach
Data on J&J’s Tecvayli and Pfizer’s Elrexfio in relapsed multiple myeloma are due soon.
Another first-in-human mystery from Merck
MK-8294 starts phase 1, but its mechanism is anybody's guess.
